Overview

Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis

Status:
Withdrawn
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Based on the limited amount of experience with plasmapheresis and CytoGam concomitant use, the researchers seek to evaluate the pharmacokinetics (drug absorption, distribution, and elimination) of this therapy. The researchers are also interested in evaluating the pharmacokinetics of the various immunosuppressant medications that patients will receive such as tacrolimus, mycophenolate mofetil and daclizumab.
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Treatments:
Antibodies
Daclizumab
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Mycophenolate mofetil
Mycophenolic Acid
Rho(D) Immune Globulin
Tacrolimus